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Source: Literature reviews of randomized controlled trails, retrospective chart reviews, metaanalysis, expert opinion, Lexicomp, and the Food and Drug Administration (FDA) served as
sources for tool development.
Keywords: PONV, drug interactions, antiemetics, QT interval prolongation, neurotransmitter
modulating agents
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Abstract
Peri-operative care providers have a myriad of medication options when developing and
implementing a plan for the management of post-operative nausea and vomiting (PONV).
However, the provider must be aware of the potential side effects, complications, and
interactions of those medications, especially when managing high-risk populations. While a perioperative antiemetic algorithm exists for the management of PONV in the general population,1
an evidence-based antiemetic tool has not been developed for patient populations at risk for
prolonged QT interval or patients who are routinely taking neurotransmitter modulating
medications. Safe practice recommendations exist but are scattered throughout the literature.
The goal of this project was to develop a tool for care providers that concatenates the evidence
and provides safe practice guidelines in the selected populations. The aims for developing this
tool were to perform a thorough literature search to gather evidence-based guidelines, to
develop the tool, and then consult an expert panel for feedback and tool validation. The end
result is a quickly accessible clinical tool for peri-operative care providers involved in PONV
management.
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Introduction
Millions of patients undergo anesthesia annually in the United States. An increasing number of
patients of advanced age are presenting to the operating room with cardiac disease. Additionally,
many patients presenting for surgery are currently on a home regimen that includes
neurotransmitter-modulating medications such as selective serotonin reuptake inhibitors (SSRI),
serotonin-norepinephrine reuptake inhibitors (SNRI), and monoamine oxidase inhibitors
(MAOI). These patients are at higher risk for peri-operative complications. Practitioners should
follow evidence-based guidelines to provide the safest and most efficient care possible to these
specified high-risk groups. Not only do standardized protocols and checklists clarify clinical
decisions for care providers, they have also been shown to improve safety.2 Anesthesia and other
peri-operative care providers must frequently make quick decisions under high-stress conditions,
so it is crucial that they are equipped with tools to help make evidence-based decisions that are
consistent with best practices.
Anesthesia providers should be able to confidently make decisions that affect the wellbeing of the patient without having to access multiple resources within the short amount of time
we care for patients in the peri-operative setting. Checklists, algorithms, protocols, and
guidelines are tools that may contribute to higher standards of care and better outcomes.2 While
not all aspects of health care can be managed by these methods, standardization helps streamline
processes and improve safety. Checklists and standardized protocols help decrease mental
burden and allow the practitioner to focus on higher-order tasks.3
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History
PONV afflicts between 9%–78% of patients receiving anesthesia,4 and is one of the major

complications from anesthesia and surgery. Nausea and vomiting pose a real threat to quality and
safety outcomes in the post-operative period. Patient demographics including gender, tobacco
use, as well as duration and type of surgery/anesthesia account for the wide variability in risk for
PONV. Many patients state PONV as their most pressing concern when they are deciding
whether or not to have a medically beneficial surgery. In addition to being uncomfortable, PONV
can also contribute to detrimental consequences such as increased length of stay, inadvertent
hospitalization, aspiration, dehydration, electrolyte imbalance, wound dehiscence,5 bleeding,
neck hematoma, and airway compromise.4,6-8 Although a clinical practice tool developed by Dr.
Christian Apfel1 is currently available to stratify PONV risk and guide prophylactic management
(Figure 1), a concise PONV tool that provides guidelines for high risk patients is not currently
available.
Determining baseline risk for PONV can be performed by assessing patient demographics.
Patient demographics that increase the risk of a patient experiencing PONV are female gender,
history of PONV or motion sickness, being a non-smoker, age < 50, general anesthesia (versus
regional), duration of anesthesia, use of volatile anesthetics and nitrous oxide, use of
postoperative opioids, and type of surgery.9,10 One point is awarded for each positive risk factor.
Then points are totaled to determine PONV risk score (Figure 1).
In addition to the Apfel risk stratification tool, Stanford University Anesthesia Department
provides guidelines for administration of specific antiemetic according to the number of positive
risk factors (Table 1).
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The impetus for tool development stemmed from clinical questions that were identified by
clinical providers. The questions that guided the aims of tool development were:
•

Do any of the commonly administered antiemetic medications actually pose a clinically
significant risk to the project populations?

•

Amongst patients taking neurotransmitter modulating medications, what commonly used
antiemetic medications should be avoided and what antiemetic medications are safe to
administer?

•

Does the administration of 5-HT3RA drugs pose a clinically significant risk in increasing
QT interval and consequently cardiac arrhythmia in susceptible patients?

•

What pre-existing factors may potentiate QT prolongation in patients who are given
antiemetics?
Review of Literature

Medications that were examined for safety of use in each of the high-risk project groups are
ondansetron, dexamethasone, metoclopramide, promethazine, prochlorperazine,
diphenhydramine, scopolamine and fosaprepitant. These 8 medications are the most routinely
used for the treatment of PONV. For example, while there are several medications in the 5HT3RA category, ondansetron is the most commonly used 5-HT3RA for the management of
PONV.
The literature review terms included all medications listed in the previous paragraph, as well
as SSRI, SNRI, MAOI, drug interactions, side effects, and adverse drug events. Other search
criteria were QT prolongation, factors predisposing patients to QT prolongation, Serotonin
Syndrome, Neuroleptic Malignant Syndrome, depression, and Parkinson’s Disease. Pediatric
research was excluded.
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Ondansetron
5-HT3RA medications are commonly used, non-sedative, generally well tolerated, and highly
effective when used for prophylaxis and treatment of PONV.11 However, a potential side effect
of the medication is prolonged QT interval. QT interval prolongation is more likely to be
experienced by susceptible patients (Table 2).12
Several studies have been undertaken to assess the safety of 5-HT3RA in patients
undergoing anesthesia who also have cardiac disease, and patients taking multiple medications
that may prolong the QT interval. A meta-analysis of 10 studies of 2,099 patients who received
ondansetron reported only insignificant electrocardiogram (EKG) changes (2 cases of atrial
fibrillation) with the risk being more likely with 32 mg doses of ondansetron.12 A prospective
single blind study comparing corrected QT (QTc) changes in patients receiving either
ondansetron or granisetron found transient prolonged QTc intervals with both, which corrected
within a few hours.13 A retrospective chart review examining 2,451 patient charts (1,429 who
received ondansetron and 1,022 who did not) failed to find a significant increase in QT interval
in patients who had received ondansetron during the peri-operative period.14 QT prolongation
risk is minimized or diminished if there is adherence to the recommended maximum dose of 16
mg.15 A 2018 review of antiemetics mentions the potential side effects of ondansetron to be
headache, dizziness, diarrhea, and constipation.11
A few case studies mention the possibility of ondansetron being linked to Serotonin
Syndrome (SS) but, no randomized controlled trials (RCT) have been identified that suggest that
ondansetron may increase the risk. Serotonin Syndrome (SS) is a condition in which increased
available serotonin can cause a host of mild- to life-threatening symptoms. Symptoms associated
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with SS are: mental status changes, agitation, myoclonus, hyperreflexia, diaphoresis, shivering,
tremor, diarrhea, incoordination, and fever.16,17 Culbertson et al.16 state that some side effects of
anticholinergics and vasopressors may mimic the condition of SS and that the clinical
presentation of SS can be highly variable due to a complex interplay of neurotransmitters.
Multiple sources confirm SS to be a potential adverse event in patients taking serotoninmodulating agents who were also given ondansetron.18,19

Dexamethasone
Dexamethasone has a large safety profile. In a RCT of 102 patients, use of dexamethasone perioperatively significantly decreased PONV, pain and pain medication usage, with low
toxicity.7,8,20 Due to the systemic effects of altered glucose and immunosuppression, concerns
about risk for increased blood glucose levels, increased wound infection, and delayed wound
healing are potential limitations for the use of dexamethasone.21 Those considerations are beyond
the scope of this project. Literature reviews, Lexicomp,19 and Goodman & Gilman18 did not
reveal any information that link dexamethasone use with QT prolongation or drug interactions
with neurotransmitter modulating agents.

Diphenhydramine
Diphenhydramine may increase the risk for prolonged QT interval,21,22 especially when
excessive doses are given.22 Diphenhydramine should be avoided in patients with Congenital
Long QT Syndrome (CLQTS).22 Shah et al.23 state that the critical dose limit for
diphenhydramine is 1 gram. During the perioperative period patients generally receive doses
ranging from 6.25–50 mg as needed every 4 hours. Practitioners should administer minimal
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effective doses of diphenhydramine to patients experiencing any factors that may contribute to
prolonged QT interval (Table 2).
A case report of a 55-year old dialysis patient who received 50 mg doses of
diphenhydramine, as needed over two consecutive days, developed prolonged QTc interval. QTc
returned to baseline after the passing of four half-lives, with no clinical sequalae.23
No search results indicated potential drug interaction when diphenhydramine is
administered in conjunction with SSRI, SNRI or MAOI.

Scopolamine
Scopolamine is an anticholinergic drug applied as a transdermal patch that may be worn for up to
72 hours. No studies reviewed, as well as Credible Meds, have identified QT prolongation as a
potential risk in conjunction with scopolamine administration.22 Kaye et al.11 state that use of
scopolamine is inappropriate for patients over the age of 65.24 Scopolamine should also be
avoided in patients with narrow angle glaucoma and patients taking aclidinium, azelastine,
cimetropium, eluxadoline, glucagon, glycopyrrolate, ipratropium, levosulpiride, orphenadrine,
paraldehyde, potassium chloride, thalidomide, tiotropium, and umeclidinium.11
While no studies correlate a drug interaction between scopolamine and SSRI, SNRI, or
MAOI medications, the provider should take special note of the patient taking centrally-acting
medications and scopolamine. Considering the centrally-acting nature of both antidepressants
and scopolamine, this medication combination comes with a warning of increased risk for mental
status changes. The administration of scopolamine may increase the risk of developing Central
Anticholinergic Syndrome (CAS).25
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Metoclopramide
Patients who receive metoclopramide may be at increased risk of experiencing tardive dyskinesia
and extrapyramidal effects, especially patients with Parkinson’s Disease.24 Metoclopramide has
a black box warning for the risk of tardive dyskinesia. 21,26 When taken concurrently with
medications listed in the project tool, there is increased risk for and a broader spectrum of
potential side effects. For instance, the combination of metoclopramide and serotoninmodulating agents can result in extrapyramidal effects, SS, and Neuroleptic Malignant Syndrome
(NMS). 21,27,28
Beers Criteria24 states that metoclopramide use should be avoided in geriatric patients
unless it is being used for gastroparesis. CredibleMeds22 assigns a conditional risk (CR) of QT
prolongation to the use of metoclopramide. Based on these findings, metoclopramide should be
avoided in patients with Parkinson’s Disease, CLQTS, or Long QT Syndrome (LQTS).
A 2018 medication review states that metoclopramide is not routinely used for PONV
prevention due to the availability of more efficacious alternatives that produce fewer side effects.
The authors state controversial findings in the literature on the efficacy of metoclopramide,
highlighting that doses of 25 – 50 mg are needed as opposed to the routine 10 mg dose. Higher
doses result in increased risk for extrapyramidal side effects.9,21

Promethazine and Prochlorperazine
Promethazine and prochlorperazine are phenothiazines (PTZ). While the pharmacodynamics of
these two medications differs, resulting in variable desirable effects and undesirable side effects,
they both may place patients at increased risk for experiencing extrapyramidal side effects. PTZs
are known to have antipsychotic, antiemetic, and sedative properties. Promethazine has
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antihistaminergic properties that may provide relief from nausea and vomiting. Care providers
administer prochlorperazine for its antipsychotic and antiemetic properties. While no studies
were identified that directly linked or stated promethazine and prochlorperazine being implicated
in SS, Culbertson et al.16 state that medications which act on any serotonin or monoamine
oxidase receptors may play a role in SS, and that medications that effect more than one receptor
may increase risk. Additional drugs found to place patients at higher risk for SS, especially with
PTZ use, include cyclobenzaprine, meperidine, paroxetine, sertraline, methadone, tramadol,
venlafaxine, fentanyl, and methylene blue.9 Lexicomp19 confirms that use of PTZs increases the
risk of SS.16,17
Promethazine and prochlorperazine may also increase the risk for a patient to experience
NMS.21 The FDA29 defines NMS as a “potentially fatal symptom complex” with symptoms such
as hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse
or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). The FDA29 reports NMS
in association with the use of promethazine and antipsychotics, including prochlorperazine.
CredibleMeds22 assigns possible risk (PR) to promethazine for prolongation of the QT
interval, states that promethazine has been found to increase QT intervals in some patients, and
that it could theoretically be dangerous for patients with CLQTS. Use in this population should
be reserved to those for whom the benefits outweigh the risks.
Of note, the FDA29 has placed a black box warning on promethazine for the risk of tissue
necrosis with parenteral/superficial intramuscular injection administration and a black box
warning on prochlorperazine for the risk of death in the elderly when prescribed as an
antipsychotic.30
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Fosaprepitant

Approved for use in the U.S. in 2008,31 fosaprepitant is the parenteral formula of the neurokinin1 receptor antagonist (NK1RA). It has not been widely adopted in the perioperative period, most
likely due to cost. Due to its recent introduction, there are relatively few studies about the drug or
its drug interactions. Fosaprepitant should be avoided in patients receiving cisapride or pimozide
due to reports of life-threatening QT prolongation.18 No studies reviewed to date list any serious
drug interactions between the NK1RA and SSRI, SNRI, or MAOI, nor do any mention QT
prolongation as a potential side effect of fosaprepitant. Aapro et al.32 performed a pooled analysis
of 4 RCTs that examined adverse effects of antiemetic regimens in 3,280 patients receiving
chemotherapy. The analysis examined the safety of 3 different antiemetic regimens all
containing NK1RAs, and found NK1RA drugs to be very safe with very few cardiac side
effect.32 With simultaneous use of dexamethasone and fosaprepitant, the dose of the
dexamethasone should be decreased due to risk of developing Cushing Syndrome and
immunosuppression.19,33

Methods
The tool was initially developed from information garnered from the literature reviews. Each
medication is listed in the tool and a guideline for use in each population is assigned to each
medication. A green check mark indicates that no literature was found to suggest that this
medication/population combination is known to be problematic. A yellow yield sign indicates
that this medication/population combination may experience serious side effects warranting
additional monitoring or observation. A red stop sign indicates that this medication/population
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combination has known serious side effects and is best avoided. Table 3 illustrates the symbol
used in the tool with the associated recommendation.
During tool development, experts were identified through the literature and invited to
participate by email invitation. Upon acceptance, each expert received the preliminary tool and
evaluation form. Multiple rounds of invitations were sent out with a total of 19 experts being
invited. The first author requested that evaluation forms and feedback be returned within two
weeks of receiving materials. Experts were sent reminder emails at the two-week point which
allotted an additional two weeks to provide feedback. This process was repeated until feedback
was received from 5 experts, the minimum number required for obtaining a 0.78 affirmation
response (AR) of consensus among four experts out of five.34 The expert panel consisted of 4
CRNAs and a pharmacist.
Experts were provided with the project tool (Table 4), legend (Table 3), an evaluation
form, the Apfel Risk Stratification Chart (Figure 1) and the Stanford PONV Guidelines Chart
(Table 1). Experts were asked to circle whether or not each recommendation in the tool was safe
or unsafe. Blank space was provided after the series of questions for each medication with the
request to place any additional comments in the space. Two experts had clarification questions
about the tool which were discussed via phone call. Additional feedback was provided via email
by one expert (Evaluation form and expert panel analyzation form available upon request).
Out of 21 items, 17 garnered full consensus amongst all experts. The exceptions were the
combination of ondansetron with SSRI/SNRIs (AR 0.6), ondansetron with MAOIs (AR 0.8),
dexamethasone with SSRI/SNRIs (AR 0.8) and dexamethasone with MAOIs (AR 0.8). An AR of
less than 0.78 required tool revision or removal.
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The expert panel recommended several changes to the project tool. One expert
recommended removing metoclopramide due to declining clinical use, and another
recommended the addition of propofol to the tool. Tool adjustment such as these require a
second review process.
The original guideline in the tool regarding ondansetron use with patients taking

SSRI/SNRI and MAOI drugs contained a green “check mark”, indicating no clinical concerns for
this combination of medications. However, after analyzing expert panel feedback, the affirmation
response of this guideline was only 0.6. Additional literature searches and consultation of
Lexicomp19 confirmed the expert panel feedback resulting in this guideline receiving a yellow
“yield mark”, indicating caution and increased observation for this patient population
A tool development collaborator recommended that a cost valuation also be assigned to
each medication. Table 5 denotes number of dollar signs and associated cost of medication at
time of publication, according to Lexicomp.19

Summary
Perioperative care providers have many factors to consider when developing a PONV regimen
for patients. Medical history, operative/anesthetic details, and the entire pharmacologic regimen
play a role in patient outcomes. When considering risk for side effects, drug interactions, and
adverse drug events, the provider must keep the role of polypharmacy in mind. This project
highlights the importance of provider pharmacologic knowledge, recognition of medications that
may increase the risk for SS, and other adverse drug events. The perioperative course is brief and
fast paced. Tools and guidelines that can be quickly accessed can be helpful to providers during
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this time. This tool can aid peri-operative care providers with evidence-based information to help
guide their clinical decisions, resulting in safer and more cost-effective care.
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Figure 1. Apfel PONV Risk Stratification Chart
(From the New England Journal of Medicine. Apfel C, Korttila K, Abdalla M, et al. A Factorial
Trial of 6 Antiemetics for the Prevention of Postoperative Nausea and Vomiting. 350, 2441 –
2451. Copyright 2004 Massachusetts Medical Society. Reprinted with permission from
Massachusetts Medical Society.)
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Risk
Score
0
1

Prevalence PONV
9%
20%

Prophylaxis:
No of Anti-emetics
0-1
1

Examples*

± Ondansetron 4 mg
Ondansetron 4 mg
± Dexamethasone 4mg
2
39%
2
Ondansetron 4 mg
+Dexamethasone 4mg
± Propofol infusion
3
60%
3
Ondansetron 4 mg
+ Dexamethasone 4 mg
+ Propofol infusion
± Scopolamine patch
4
78%
4
Ondansetron 4 mg
+ Dexamethasone 4 mg
+ Propofol infusion
+ Scopolamine patch
* Combinations should be with drugs that have a different mechanism of action.
Table 1. Stanford University Anesthesia Department PONV Guidelines Chart
(Base Prophylaxis Risk Score Table reproduced by permission of Ether, Stanford Department of
Anesthesiology, Perioperative and Pain Medicine. Accessed from
http://ether.stanford.edu/policies/PONV.prophylaxis.guidelines.html)
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Factors That Increase Risk for QT Prolongation
Pheochromocytoma
Hypokalemia
Hypothermia
Bradycardia
Hypomagnesemia
Hemodialysis
AV Block
Hypocalcemia
Heart disease
Cardiac pauses
Female gender
Congenital Long QT
Takotsubo cardiomyopathy
Hypothyroidism
Syndrome
12,28
Table 2. List of Factors that May Increase the Risk of QT Prolongation.

Symbol

Recommendation
Literature finds no clinically significant risk.

Literature finds potential risks. Additional monitoring or
observation for interactions may be beneficial.
Literature reports known or observed drug interactions or
side effects or higher risk for drug interactions or side
effects.

Table 3. Antiemetic Decision Tool for High Risk Anesthesia Patients Legend
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Antiemetic

Antiemetic Decision Tool for High Risk Anesthesia Patients
QT Prolongation SSRI/SNRI
MAOI
Cost
Risk

Ondansetron

$

Comments: Avoid in CLQTS. Use caution in patients with hypokalemia/hypomagnesemia/other
electrolyte disturbances, bradycardia/brady-arrhythmias/patients on medications that cause
bradycardia, underlying heart disease/CHF, and patients taking other QT prolonging medications
(especially chemotherapeutic agents). Ondansetron + promethazine may increase the risk for
prolonged QT interval, consider obtaining baseline ECG and monitor for ECG changes during
use.
Dexamethasone

$

Comments: Reduce dose of dexamethasone in concomitant use of NK-1 agents D/T risk of high
serum dexamethasone levels (apparent for 8 days after NK1 use).
Diphenhydramine

$

Comments: Avoid in CLQTS. Avoid excessive dose.
Scopolamine

$$

Comments: Scopolamine + SSRI/SNRI/MAOI may increase patient risk for developing CAS,
especially in patients taking multiple agents that affect neurotransmitters or patients over age 65.
Observe for mental status changes and Central Anticholinergic Syndrome when scopolamine is
given with antidepressants. Avoid use in patients with narrow angle glaucoma and patients taking
aclidinium, azelastine, cimetropium, eluxadoline, glucagon, glycopyrrolate, ipratropium,
levosulpiride, orphenadrine, paraldehyde, potassium chloride, thalidomide, tiotropium, and
umeclidinium.
Promethazine

$
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Comments: Avoid in CLQTS. Best to avoid concomitant use of metoclopramide and
promethazine. This combination may increase risk for QT prolongation. Consider obtaining
baseline ECG and monitor for ECG changes during co-administration. Co-administration of
promethazine and metoclopramide may increase the risk of CNS depression and extrapyramidal
effects.. Best to avoid use with other potentially QT prolonging medications.
Prochlorperazine

$$

Comments: The combination of metoclopramide and prochlorperazine can result in
extrapyramidal effects and Neuroleptic Malignant Syndrome. Prochlorperazine may increase the
risk of QT interval prolongation. Best to avoid use with other potentially QT prolonging
medications. The combination of prochlorperazine with SSRI/SNRI, ondansetron,
metoclopramide, promethazine, Isoflurane and Sevoflurane may increase the risk of QT
prolongation.
Metoclopramide

$

Comments: Avoid in CLQTS, avoid in pts with low/high K+ or Mag or other electrolyte
disturbances. Use with caution in elderly, patients with cardiac conduction
disturbances/bradycardia, or pts taking other QT prolonging drugs. Avoid in any serotonin
modulating agents, including tramadol/Ultram D/T risk of extrapyramidal activity and
Neuroleptic Malignant Syndrome. The combination of metoclopramide and prochlorperazine can
result in extrapyramidal effects and Neuroleptic Malignant Syndrome. medications.
Aprepitant

$$$$

Comments: Reduce dose of dexamethasone in concomitant use of NK-1 agents D/T risk of high
serum dexamethasone levels (apparent for 8 days after NK1 use).

Table 4. Project Tool
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Cost Scoring
System

$

$$

$$$

$$$$

Cost range

$0.10 -

>$5.00 -

>$50.00 –

> $400.00 –

$5.00

< $50.00

< $400.00

< $500.00

Table 5. Comparative Cost Table of Antiemetics Examined in Project Tool
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